DME

Why not vitrectomy for vitreous opacities?

Why pars plana vitrectomy has come of age for vitreous opacities in selected patients.

AAO Report: New insights into ILM tears, trial readouts and more

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Mixed results in DME, PDR hemorrhage, ROP

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Treat and extend: An international view

Three experts from Canada, Switzerland and Israel provide insights into the nuances of adherence, treatment intervals and emerging therapies.

DRCR Protocol V in the real world

Here’s why we should feel more confident observing patients with center-involving diabetic macular edema with good vision.

20 milestones ahead in AMD, DME meds

A look at chemical and biologic agents queued this year or next for key steps toward commercialization.

What Vascular Changes May Tell us About Macular Edema and Disease Burden

How quantitative assessment of perfusion and leakage dynamics may help direct management of retinal vascular disease.

Managing DME During Pregnancy

Intravitreal steroids may be considered in cases refractory to blood glucose control and laser.

Lessons from DRCR.net Protocol T

What we can take from the study and apply in our clinics.

Selecting Patients for the Iluvien Implant

Sustained-release device emerges after a decade-long journey.